FEMY
Neutral signalScored 2026-08-12 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Femasys Inc.
- Nom
- Femasys Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Instruments & Supplies
- Bourse
- NASDAQ
- Capitalisation
- $12.6M
- Employés
- 53
- PDG
- Kathy Lee-Sepsick
- Site web
- https://www.femasys.com
- Marché
- AIMDAPLMBCTXCOCHCRISDARE
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 15 625 titres (~50 000,00 $ US)
- Insiders
- Lee-Sepsick Kathy
- Total bought
-
$50,000
Avg buy (VWAP, 90d window) $3.20 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-07
- Last synced
-
2026-08-13 10:04:48
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-07 | Canning John Charles | Buy · P | 4,375 | $3.20 | $14,000 | Form 4 |
| 2026-08-07 | Elefant Dov | Buy · P | 15,625 | $3.20 | $50,000 | Form 4 |
| 2026-08-07 | Lee-Sepsick Kathy | Buy · P | 15,625 | $3.20 | $50,000 | Form 4 |
| 2026-08-07 | Mifek Jeffrey Gerald | Buy · P | 3,125 | $3.20 | $10,000 | Form 4 |
| 2026-08-07 | Sipos Jeremy Alexander | Buy · P | 3,125 | $3.20 | $10,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-12 Drivers: fundamentals. Moteurs : fondamentaux.
FEMY presents a meaningful event-driven catalyst — an insider cluster buy aligned with a $30M private placement and FemBloc patent news (catalyst score 70, confidence 0.75) — that warrants monitoring despite severely…
The first sentence of the analysis written for FEMY on 2026-08-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 4.53 · operating margin -767% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 62.0% | 66.6% | 64.5% | 63.4% | 68.6% | |
| Ebit Margin | -729.8% | -1056.0% | -1313.2% | -943.0% | -637.0% | |
| Ebitda Margin | -692.7% | -1002.5% | -1228.5% | -869.3% | -555.3% | |
| Operating Profit Margin | -767.0% | -1091.8% | -1353.4% | -961.7% | -706.7% | |
| Pretax Profit Margin | -812.2% | -1154.4% | -1328.7% | -944.1% | -638.6% | |
| Continuous Operations Profit Margin | -812.3% | -1155.0% | -1329.1% | -944.6% | -639.0% | |
| Net Profit Margin | -812.3% | -1155.0% | -1329.1% | -944.6% | -639.0% | |
| Bottom Line Profit Margin | -812.3% | -1155.0% | -1329.1% | -944.6% | -639.0% | |
| Current Ratio | 4.526 | 0.935 | 7.589 | 9.250 | 15.148 | |
| Quick Ratio | 2.947 | 0.580 | 7.371 | 8.964 | 15.025 | |
| Solvency Ratio | -1.197 | -1.770 | -1.419 | -6.355 | -2.929 | |
| Cash Ratio | 2.548 | 0.402 | 7.111 | 8.484 | 14.646 | |
| Price To Earnings Ratio | -1.226 | -1.310 | -1.048 | -0.928 | -6.094 | |
| Price To Earnings Growth Ratio | 0.028 | 0.135 | 0.254 | -0.018 | -0.719 | |
| Forward Price To Earnings Growth Ratio | 0.028 | 0.135 | 0.254 | -0.018 | -0.719 | |
| Price To Earnings Diluted Ratio | -1.226 | -1.310 | -1.048 | -0.928 | -6.094 | |
| Price To Earnings Diluted Growth Ratio | 0.028 | 0.135 | 0.254 | -0.018 | -0.719 | |
| Price To Book Ratio | 3.881 | 10.629 | 0.817 | 0.697 | 1.748 | |
| Price To Sales Ratio | 9.933 | 15.036 | 13.993 | 8.807 | 39.024 | |
| Price To Free Cash Flow Ratio | -1.186 | -1.212 | -1.313 | -0.954 | -5.589 | |
| Price To Operating Cash Flow Ratio | -1.219 | -1.260 | -1.330 | -0.990 | -5.805 | |
| Debt To Assets Ratio | 0.227 | 0.598 | 0.241 | 0.032 | 0.035 | |
| Debt To Equity Ratio | 0.800 | 3.230 | 0.365 | 0.036 | 0.038 | |
| Debt To Capital Ratio | 0.445 | 0.764 | 0.267 | 0.034 | 0.036 | |
| Long Term Debt To Capital Ratio | 0.351 | 0.000 | 0.188 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.531 | 5.400 | 1.512 | 1.108 | 1.085 | |
| Working Capital Turnover Ratio | 0.374 | 0.167 | 0.066 | 0.066 | 0.095 | |
| Operating Cash Flow Ratio | -5.140 | -2.265 | -3.694 | -7.024 | -4.687 | |
| Operating Cash Flow Sales Ratio | -8.150 | -11.935 | -10.523 | -8.897 | -6.723 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.028 | 1.039 | 1.013 | 1.038 | 1.039 | |
| Debt Service Coverage Ratio | -8.400 | -2.331 | -79.653 | -67.792 | -32.715 | |
| Interest Coverage Ratio | -9.301 | -11.091 | -87.722 | -861.576 | -433.621 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -3.597 | 0.000 | -75.953 | -43.787 | |
| Operating Cash Flow Coverage Ratio | -3.979 | -2.613 | -1.683 | -19.738 | -8.009 | |
| Capital Expenditure Coverage Ratio | -35.601 | -25.527 | -78.382 | -26.338 | -25.844 | |
| Dividend Paid And Capex Coverage Ratio | -35.601 | -25.527 | -78.382 | -26.338 | -25.844 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.146 | -1.744 | 0.001 | 0.171 | -3.396 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 62.0% | ▼-4.6% | ▼-3.0% |
| Ebit Margin | -729.8% | ▲326.2% | ▲206.0% |
| Ebitda Margin | -692.7% | ▲309.8% | ▲177.0% |
| Operating Profit Margin | -767.0% | ▲324.8% | ▲209.1% |
| Pretax Profit Margin | -812.2% | ▲342.2% | ▲163.4% |
| Continuous Operations Profit Margin | -812.3% | ▲342.8% | ▲163.7% |
| Net Profit Margin | -812.3% | ▲342.8% | ▲163.7% |
| Bottom Line Profit Margin | -812.3% | ▲342.8% | ▲163.7% |
| Current Ratio | 4.526 | ▲3.591 | ▼-2.964 |
| Quick Ratio | 2.947 | ▲2.367 | ▼-4.030 |
| Solvency Ratio | -1.197 | ▲0.573 | ▲1.537 |
| Cash Ratio | 2.548 | ▲2.146 | ▼-4.090 |
| Price To Earnings Ratio | -1.226 | ▲0.084 | ▲0.895 |
| Price To Earnings Growth Ratio | 0.028 | ▼-0.107 | ▲0.092 |
| Forward Price To Earnings Growth Ratio | 0.028 | ▼-0.107 | ▲0.092 |
| Price To Earnings Diluted Ratio | -1.226 | ▲0.084 | ▲0.895 |
| Price To Earnings Diluted Growth Ratio | 0.028 | ▼-0.107 | ▲0.092 |
| Price To Book Ratio | 3.881 | ▼-6.748 | ▲0.327 |
| Price To Sales Ratio | 9.933 | ▼-5.102 | ▼-7.425 |
| Price To Free Cash Flow Ratio | -1.185 | ▲0.027 | ▲0.865 |
| Price To Operating Cash Flow Ratio | -1.219 | ▲0.041 | ▲0.902 |
| Debt To Assets Ratio | 0.227 | ▼-0.371 | ▲0.000 |
| Debt To Equity Ratio | 0.800 | ▼-2.429 | ▼-0.093 |
| Debt To Capital Ratio | 0.445 | ▼-0.319 | ▲0.135 |
| Long Term Debt To Capital Ratio | 0.351 | ▲0.351 | ▲0.243 |
| Financial Leverage Ratio | 3.531 | ▼-1.869 | ▲1.003 |
| Working Capital Turnover Ratio | 0.374 | ▲0.208 | ▲0.221 |
| Operating Cash Flow Ratio | -5.140 | ▼-2.875 | ▼-0.578 |
| Operating Cash Flow Sales Ratio | -8.150 | ▲3.785 | ▲1.096 |
| Free Cash Flow Operating Cash Flow Ratio | 1.028 | ▼-0.011 | ▼-0.003 |
| Debt Service Coverage Ratio | -8.400 | ▼-6.069 | ▲29.778 |
| Interest Coverage Ratio | -9.301 | ▲1.791 | ▲271.362 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲3.597 | ▲24.667 |
| Operating Cash Flow Coverage Ratio | -3.979 | ▼-1.367 | ▲3.225 |
| Capital Expenditure Coverage Ratio | -35.601 | ▼-10.074 | ▲2.738 |
| Dividend Paid And Capex Coverage Ratio | -35.601 | ▼-10.074 | ▲2.738 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.146 | ▲0.598 | ▲0.076 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $22.8M | $24.5M | $15.0M | $10.6M | $46.0M | |
| Enterprise value | $18.2M | $28.5M | -$15K | -$1.8M | $22.2M | |
| EV / Sales | 7.94x | 17.48x | -0.01x | -1.49x | 18.86x | |
| EV / Op. cash flow | -0.97x | -1.47x | 0.00x | 0.17x | -2.81x | |
| EV / Free cash flow | -0.95x | -1.41x | 0.00x | 0.16x | -2.70x | |
| EV / EBITDA | -1.15x | -1.74x | 0.00x | 0.17x | -3.40x | |
| Net debt / EBITDA | 0.29x | -0.24x | 1.14x | 1.18x | 3.63x | |
| Current ratio | 4.53x | 0.94x | 7.59x | 9.25x | 15.15x | |
| Income quality | 1.00x | 1.03x | 0.79x | 0.94x | 1.05x | |
| Graham net-net | -$1 | -$4 | $17 | $20 | $38 | |
| Tax burden | 100.0% | 100.1% | 100.0% | 100.1% | 100.1% | |
| Interest burden | 111.3% | 109.3% | 101.2% | 100.1% | 100.3% | |
| Working capital | $12.8M | -$560K | $20.1M | $12.6M | $23.9M | |
| Invested capital | $16.1M | $2.9M | $23.6M | $14.4M | $26.2M | |
| Return on assets | -89.9% | -151.2% | -51.3% | -67.4% | -26.4% | |
| Operating ROA | -106.1% | -88.5% | -65.0% | -51.0% | -46.1% | |
| Return on tangible assets | -90.5% | -152.0% | -51.3% | -67.5% | -26.4% | |
| Return on equity | -317.4% | -816.5% | -77.6% | -74.8% | -28.6% | |
| Return on invested capital | -100.1% | -181.7% | -57.8% | -73.0% | -30.3% | |
| Return on capital employed | -102.9% | -460.5% | -58.7% | -75.5% | -31.0% | |
| Earnings yield | -81.8% | -76.8% | -95.0% | -107.3% | -16.4% | |
| Free cash flow yield | -84.4% | -82.5% | -76.2% | -104.9% | -17.9% | |
| Capex / Op. cash flow | -2.8% | -3.9% | -1.3% | -3.8% | -3.9% | |
| Capex / Depreciation | 65.3% | 87.4% | 15.9% | 45.8% | 31.8% | |
| Capex / Sales | 22.9% | 46.8% | 13.4% | 33.8% | 26.0% | |
| SG&A / Sales | 483.6% | 635.7% | 700.4% | 496.6% | 379.0% | |
| R&D / Sales | 330.4% | 504.4% | 672.5% | 482.0% | 346.2% | |
| Stock comp / Sales | 34.5% | 27.3% | 63.0% | 18.6% | 16.4% | |
| Intangibles / Total assets | 0.7% | 0.5% | 0.0% | 0.0% | 0.1% | |
| Days sales outstanding | 98d | 109d | 34d | 23d | 26d | |
| Days payables outstanding | 766d | 951d | 1093d | 422d | 439d | |
| Operating cycle | 2500d | 2150d | 674d | 384d | 231d | |
| Cash conversion cycle | 1734d | 1199d | -418d | -38d | -208d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-12 Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents -- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the Company''s non-surgical permanent birth control technology. These patents broaden and extend FemBloc''s global intellectual property protection, complementing existing patents covering its delivery system and further strengthening the technology''s competitive position in a highly regulated market with rigorous clinical and regulatory requirements.
- 2026-08-07 Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million -- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has entered into a securities purchase agreement (the “Purchase Agreement”) for a $30 million private placement with certain accredited investors. The financing was led by new institutional investor Nantahala Capital, with participation from additional new healthcare-focused funds, including Rosalind Advisors, Inc., as well as members of Femasys'' management team. The private placement is subject to customary closing conditions and is expected to close on or around August 10, 2026.
- 2026-06-24 Femasys Regains Compliance with Nasdaq Listing Requirements ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today that it received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing and that the matter is now closed.
- 2026-05-13 Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --